Liquidia Corp LQDA

US Pharmaceuticals

$84.11 ▼ -3.10% ($-2.69)

🗓️ Earnings Next Week

Open $86.24

Prev Close $86.80

Day Range $82.53 – $87.46

52W Range $16.82 – $91.10

Market Cap $7.48B

P/E (TTM) 335.34

Beta 0.58

EPS (TTM) $0.16

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-07-26
Shares Out.	88,930,000
Website	liquidia.com/ ↗
Phone	19193284400
Employees	216
Revenue	$132.9M
Gross Profit	$121.0M
Net Income	$52.9M
Free Cash Flow	$41.1M
Total Assets	$401.5M
Total Liabilities	$293.0M
Equity	$108.6M

About Liquidia Corp

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Liquidia Corp is a publicly traded company under the ticker symbol LQDA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.